Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alnylam Pharmaceuticals Inc

ALNY ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$228.65

▲ +0.67%

Market Cap $30.60B · Vol 520.43K

Key Metrics

P/E Ratio

38.91

FWD: 26.45

Market Cap

$30.60B

Large Cap

Div Yield

N/A

EPS Growth

+183.80%

YoY

RSI (14)

33.24

Momentum

Beta

0.30

vs Market

52W High

$495.31

53.84% below

52W Low

$197.92

15.53% above

Volume

520.43K

Avg 611.99K

P/B

66.70

Price-to-book

ROE

73.28%

Return on equity

Free Float

99.72%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Alnylam Pharmaceuticals Inc (ALNY) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALNY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.31%

-18.71%

-22.08%

-27.27%

YTD

-42.50%

-48.35%

+26.94%

+16.34%

Financials & Valuation

TTM · Annual

Total Revenue	$3.71B
Net Income	$313.75M
Revenue Growth (YoY)	+66.86%
Gross Margin	81.64%
Operating Margin	13.51%
Net Profit Margin	8.45%
ROE	73.28%
ROA · ROIC	7.02% · 18.55%

P/E Ratio	38.91
Forward P/E (FY1)	26.45
PEG Ratio	0.83
P/S	14.42
P/B	66.70
P/FCF	115.08
EPS Growth	+183.80%
Outstanding Shares	133.81M

Technical Indicators

50-Day SMA	$273.17
200-Day SMA	$336.70
RSI (14)	33.24
Beta	0.30
52-Week High	$495.31
52-Week Low	$197.92

Volume Today	520.43K
Avg Daily Volume (30D)	611.99K
Relative Volume	0.85x
Volatility (10D)	49.77
Volatility (30D)	104.34
Free Float	99.72%

Analyst Consensus

BUY

Current Price $228.65

Mean Target $373.14

52W Low$197.92 52W High$495.31

Current

Target

$197.92 $495.31

Current Analyst target

+63.19% upside potential · 29 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S7FTC8

ISINUS02043Q1076

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.